Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial
Phase of Trial: Phase I/II
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs 64Cu-MeCOSar-Octreotate (Primary) ; 67Cu-MeCOSar-Octreotate-Clarity-Pharmaceuticals (Primary)
- Indications Meningioma
- Focus Adverse reactions
- Sponsors Clarity Pharmaceuticals
- 25 Sep 2019 Planned End Date changed from 24 Jul 2020 to 25 Mar 2021.
- 29 Apr 2019 Planned End Date changed to 24 Jul 2020.
- 29 Apr 2019 Planned primary completion date changed to 24 Jul 2020.